Form 8-K - Current report:
SEC Accession No. 0001641172-25-001969
Filing Date
2025-04-01
Accepted
2025-04-01 06:07:00
Documents
22
Period of Report
2025-03-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 66255
2 ex4-1.htm EX-4.1 121548
3 ex4-2.htm EX-4.2 114125
4 ex4-3.htm EX-4.3 113291
5 ex5-1.htm EX-5.1 12967
6 ex10-1.htm EX-10.1 280921
7 ex10-2.htm EX-10.2 115861
8 ex99-1.htm EX-99.1 15450
9 ex99-2.htm EX-99.2 15937
  Complete submission text file 0001641172-25-001969.txt   1262870

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE cldi-20250328.xsd EX-101.SCH 3813
11 XBRL DEFINITION FILE cldi-20250328_def.xml EX-101.DEF 26683
12 XBRL LABEL FILE cldi-20250328_lab.xml EX-101.LAB 36817
13 XBRL PRESENTATION FILE cldi-20250328_pre.xml EX-101.PRE 25307
24 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5966
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 25796389
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)